Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) Net Margin (2017 - 2026)

Lexaria Bioscience's Net Margin history spans 10 years, with the latest figure at 7000.0% for Q1 2026.

  • Quarterly results put Net Margin at 7000.0% for Q1 2026, up 544828.0% from a year ago — trailing twelve months through Feb 2026 was 2581.52% (up 79419.0% YoY), and the annual figure for FY2025 was 1685.74%, up 43648.0%.
  • Net Margin for Q1 2026 was 7000.0% at Lexaria Bioscience, up from 1551.72% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 7000.0% in Q1 2026 to a low of 79710.21% in Q3 2022.
  • The 5-year median for Net Margin is 1992.29% (2024), against an average of 2649.88%.
  • The sharpest move saw Net Margin tumbled -7969154bps in 2022, then surged 8361379bps in 2023.
  • Year by year, Net Margin stood at 1841.71% in 2022, then crashed by -57bps to 793.24% in 2023, then skyrocketed by 85bps to 1468.01% in 2024, then rose by 6bps to 1551.72% in 2025, then surged by 351bps to 7000.0% in 2026.
  • According to Business Quant data, Net Margin over the past three periods came in at 7000.0%, 1551.72%, and 2183.91% for Q1 2026, Q3 2025, and Q2 2025 respectively.